<?xml version="1.0"?>
  <rss version="2.0">
    <channel>
      <title>Erythromycin Ophthalmic Ointment News : GoldBamboo.com</title>
      <link>http://goldbamboo.com/</link>
      <description>Erythromycin Ophthalmic Ointment News from GoldBamboo.com</description>
      <language>en-us</language>
      <copyright>&amp;copy; 2005, Gold Bamboo LLC, All Rights Reserved</copyright>
      
	<item>
        <title>Bioengineering Efficient Antibiotic Biosynthesis In E. Coli</title>
        <link>http://goldbamboo.com/news-a221937.html</link>
        <description>An erythromycin-producing E. coli recombinant strain with an antibiotic-overproducing mutation in the mycarose biosynthesis pathway produced second-generation mutants capable of directed biosynthesis of enhanced precursor macrolide antibiotics.</description>
		 <pubDate>Wed, 21 Feb 2007 04:00 EST</pubDate>
	</item>
	<item>
        <title>Bioengineering Efficient Antibiotic Biosynthesis In E. Coli</title>
        <link>http://goldbamboo.com/news-a219496.html</link>
        <description>The pathways underlying the production of antibiotics are now quite well known. For example, the antibacterial activity of erythromycin, an important polyketide antibiotic precursor, requires the transfer of two unusual sugars called mycarose and desosamine (both glycosyl groups) onto the nonsugar part of the glycoside molecule (macrocyclic aglycone). [click link for full article]</description>
		 <pubDate>Wed, 07 Feb 2007 01:00 EST</pubDate>
	</item>
	<item>
        <title>Lux Biosciences Initiates LUMINATE Pivotal Clinical Trials Of Its Next-Generation Calcineurin Inhibitor, LX211, In Uveitis</title>
        <link>http://goldbamboo.com/news-a221855.html</link>
        <description>Lux Biosciences, Inc., a privately held biotechnology company specialized in the field of ophthalmic  diseases, announced today that the company had begun treating patients in its LUMINATE (Lux Uveitis Multicenter Investigation of a New Approach to TreatmEnt) pivotal clinical trial program of LX211, the company's next-generation calcineurin inhibitor. [click link for full article]</description>
		 <pubDate>Wed, 21 Feb 2007 08:00 EST</pubDate>
	</item>
	<item>
        <title>Journal Theme Issue Highlights Advances In Eye Disease Genetics</title>
        <link>http://goldbamboo.com/news-a220908.html</link>
        <description>Research on the genetic basis of eye diseases is enabling rapid progress in the diagnosis and treatment of these conditions, according to a series of articles on ophthalmic genetics in the February issue of Archives of Ophthalmology, one of the JAMA/Archives journals. [click link for full article]</description>
		 <pubDate>Thu, 15 Feb 2007 04:00 EST</pubDate>
	</item>
	<item>
        <title>Sirion Therapeutics Acquires U.S. License To Develop New Treatment For Viral Eye Infection</title>
        <link>http://goldbamboo.com/news-a216115.html</link>
        <description>Sirion Therapeutics, Inc., an ophthalmic-focused biopharmaceuticals company, announced today that it has reached an exclusive licensing agreement with Laboratoires Thea of France for the U.S. rights to develop and market a topical ophthalmic gel containing ganciclovir for the treatment of certain viral and superficial eye infections. [click link for full article]</description>
		 <pubDate>Thu, 18 Jan 2007 08:00 EST</pubDate>
	</item>
	

    </channel>
  </rss>
